May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Sodium Hyaluronate Gel (Healon and Healon 5) as a Drug Release System for Hydrophilic Steroid Formulation in Ophthalmic Surgery: Release Kinetics and Antiproliferative Potential
Author Affiliations & Notes
  • M.S. Spitzer
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • R.T. Kaczmarek
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • A. Sierra
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • E. Yoeruek
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • K.U. Bartz–Schmidt
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • P. Szurman
    Ophthalmology, Tuebingen University Eye Hospital, Tuebingen, Germany
  • Footnotes
    Commercial Relationships  M.S. Spitzer, None; R.T. Kaczmarek, None; A. Sierra, None; E. Yoeruek, None; K.U. Bartz–Schmidt, None; P. Szurman, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5127. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.S. Spitzer, R.T. Kaczmarek, A. Sierra, E. Yoeruek, K.U. Bartz–Schmidt, P. Szurman; Sodium Hyaluronate Gel (Healon and Healon 5) as a Drug Release System for Hydrophilic Steroid Formulation in Ophthalmic Surgery: Release Kinetics and Antiproliferative Potential . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5127.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the in vitro release kinetics, the safety and the antiproliferative potential of a concentrated hydrophilic steroid formulation from commercially available sodium hyaluronate gels (HA) used as a slow release system.

Methods: : Dexamethasone and Healon (HA) or Healon 5 (HA5) were mixed preparing HA formulations containing dexamthasone in concentrations from 4 mg/ml to 20 mg/ml (7.7 mM to 38.7 mM). Non–cumulative and cumulative release into balanced salt solution or PBS as a receiver fluid was measured spectrophotometrically over 2 to 6 days. The release of the steroid was plotted as function of the square root of time. To assess the antiproliferative potential of HA containing dexamethasone monolayer cultures of human retinal pigment epithelium (ARPE19) and human tenon fibroblast (HTFB) cells were used Cellular proliferative activity was monitored by BrdU–incorporation into cellular DNA. For cytotoxicity assays ARPE19 and HTFB cells were grown to confluence and then cultured in a serum–deficient medium to ensure a static milieu. MTT assay after one day and life/dead cell–mediated cytotoxicity kit after 6 days of incubation were used to exclude cytotoxicity.

Results: : The release kinetics from HA and HA 5 were identical – steady state was achieved after 48 hours in the non–cumulative measurements. 50% of the drug was released by 6 hours into BSS and PBS. The release rate slowed down after 24 hours. No kinetic differences were seen between the higher and the lower concentrations of dexamethasone. The release plotted as a function of the square root of time was consistent with a largely diffusion–controlled release system. Dexamethasone loaded HA showed a significant antiproliferative effect on ARPE19 and HTFB cells at dexamthasone concentrations of 0.9 mM or higher. No cytotoxicity could be seen after 1 and 6 days.

Conclusions: : Dexamethasone loaded HA shows extended release of steroid over up to 2 days in concentrations high enough to inhibit proliferation of HTFB and RPE cells. Thus this formulation may be a valuable, easy to prepare adjunct for sustained antiproliferative drug effect in glaucoma surgery or other ophthalmic procedures.

Keywords: drug toxicity/drug effects • wound healing • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×